Article

Genentech changes distribution channels for bevacizumab

San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).

San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).

First the Southern San Francisco-based biotech company needs FDA clearance to continue allowing wholesalers to sell the drug to compounding pharmacies.

The company is forbidden by the FDA to use bevacizumab for any unapproved purposes.

Currently Genentech has postponed the restriction on bevacizumab sales until January 2008 so physicians can find other ways to obtain the product. Discussion also will be continued with the American Academy of Ophthalmology (AAO) and the American Society of Retina Specialists.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.